Firebrick Plans and Prospects

In response to the post by @Amit9997, I am happy to provide an overview of our plans and prospects for the remainder of 2025 and a view on what to expect in 2026. This overview will be consistent with recent and past announcements, and statements made in recent interviews and webinars. I will provide this over the weekend.

In the meantime, here are some points for all investors to consider:

1. Firebrick is not a biotech stock; we do not have in front of us any high-risk clinical trial or regulatory events, which if negative, can be devastating for biotech firms; historically in Australia, most biotechs have experienced such an outcome and it has led to complete loss of shareholder value. My PhD research was specifically on this subject and if you want to learn more, go to: https://bit.ly/3Iin0ZM. Unlike many Australian biotech companies, which could be worth $1B one day and nothing the next, Firebrick does not have any significant R&D risk and there is no scenario where (in my opinion) Firebrick is worth nothing.
2. With Firebrick, the horizon for value creation and realization is not short-term. Unlike biotechs that can go up and down dramatically based on intangible perceived value events - such as the anticipation and then realization of a clinical trial or regulatory outcome - Firebrick is building value incrementally and steadily by growing the awareness, adoption, partnering and sales of a much-needed, but novel product. Don't expect an announcement that delivers 10x results overnight.
3. It is not a short-term journey: Don't be obsessed with short-term sales value and profit figures - we are not there yet. We are one year into the marketing of a much-needed but novel product in one or two markets. In the US, our market potential is limited because of its classification as a nasal cleanser, so we have only one real market where we have properly launched Nasodine as a "nasal antiseptic" and that's Singapore with a population of only 6 million. Sales and profit growth will come (in the medium term) from increased awareness, distribution and sales in Singapore, but that small market alone, while valuable as a showcase of what Nasodine can achieve, will not make us profitable as a company. It is just the tip of a very large iceberg. Next year we expect to launch in the Philippines, where we have a truly committed and supportive partner in place (SV More) and a population of 119 million - nearly 20 times the size of Singapore; moreover, unlike Singapore, we do not have any marketing costs to drain profits. SV More have been seeding the market with samples of Nasodine to ENTs (ear nose and throat specialists) for several years, and they (SV More) are so excited about the Philippines opportunity for Nasodine that they invested $1.1m in Firebrick in March.
4. Dimensions of value growth: FRE value growth will come from three variables that translate into EV (enterprise value) and thereby into market cap: (1) Time: within each market, sales will grow over time as awareness and distribution grows with a market; a discounted net present value (NPV) can be calculated for each curve through and beyond the life of our patents (earliest to expire is 2035); the NPV from the Singapore market for the nasal spray alone is low, because of its small population and the fact that we are funding the marketing ourselves (not through a partner) (2) Markets: each new market adds a new sales growth curve and associated NPV, again adding to EV; the NPV from the sales of the nasal spray in the Philippines could be much more than 20x that of Singapore, because of the larger population and the fact that we are not funding the marketing in the Philippines; there are lots of other markets in the region that are in our sights, each adding new NPV potential and through partnerships where we do not fund the marketing; and (3) New products: FRE is not a single product company; we have at least three new Nasodine-brand products we could launch launch in the next 6-12 months; each new product adds a new NPV value to the company and benefits from the synergy of the Nasodine portfolio effect.
5. FRE is more than an investment opportunity; over 13 years, we have created a product that the world needs more than ever, and is backed by real R&D, clinical trials, patents and peer-reviewed publications. We want shareholders who believe in our mission. We want you to consider FRE as not just as an investment opportunity, but as a righteous quest by an Australian company that seeks to benefit the world. I'm sure that sounds corny, but that's what keeps us going.

The post on the prospects, plans and news-flow for the next 6-12 months will follow shortly under this thread.